A Study of GC203 TIL in Advanced Malignant Solid Tumors

Key facts

Sponsor

Shanghai Juncell Therapeutics

Intervention

Engineering Tumor Infiltrating Lymphocytes(biological)

Enrollment

18 target

Eligibility

18-75 years · All sexes

Timeline

2024 – 2027

Study locations (1)

• Fudan University Shanghai Cancer Center, Shanghai, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Mucolipidosis type II

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT07012031
  Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
  National Cancer Institute (NCI)
• RECRUITINGPHASE1NCT07377435
  DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
  David Avigan
• RECRUITINGPHASE1NCT07032714
  Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
  Massachusetts General Hospital
• RECRUITINGPHASE1, PHASE2NCT06903377
  Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
  Suzhou Zelgen Biopharmaceuticals Co.,Ltd
• RECRUITINGPHASE1NCT06994143
  A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
  Cullinan Therapeutics Inc.
• RECRUITINGPHASE1NCT06861543
  The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)
  Peking Union Medical College Hospital
• RECRUITINGPHASE1, PHASE2NCT06083207
  A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
  Innovent Biologics (Suzhou) Co. Ltd.
• RECRUITINGPHASE1, PHASE2NCT06495723
  Polyspecific Antibodies in Lymphoproliferative T-cell Disorders
  Xenothera SAS

See all trials for Mucolipidosis type II →